Clinical Cancer Research
Clinical Cancer Research (Clin. Cancer Res.) is a clinical oncology journal published by the American Association for Cancer Research itself. Founded in 1995, it concentrates on the translation of molecular biological findings into clinical application, appears twice a month, and had a 2025 impact factor of 10.9.《临床癌症研究》（Clinical Cancer Research''''，缩写 Clin. Cancer Res.''）是美国癌症研究协会自行出版的临床肿瘤学刊物，1995 年创刊。该刊以分子生物学发现向临床应用的转化为主题，现为每月两期，二〇二五年影响因子为 10.9。
Scope
The journal's editorial stance is that molecular findings have to reach the clinic: however novel the discovery, a paper must show what it means for the diagnosis, classification, treatment or drug resistance of patients with cancer. Coverage runs from early clinical trials to molecular characterisation and concentrates on:本刊的取稿立场是「分子机制必须落到临床」：一篇论文不论分子发现多么新颖，都要说明它对肿瘤患者的诊断、分型、治疗或耐药有何意义。收文覆盖从早期临床研究到分子表征的完整链条，重点包括：
- Clinical trials of targeted therapy: trials of small-molecule and antibody agents, dose and schedule optimisation, efficacy and safety assessment, and combination strategies.靶向治疗临床研究： 小分子靶向药物与抗体药物的临床试验、剂量与方案优化、疗效与安全性评价、联合治疗策略。
- Resistance and drug sensitivity: mechanisms of acquired resistance, biomarkers of sensitivity and resistance, strategies to overcome resistance, and tumour heterogeneity and clonal evolution.耐药与药物敏感性： 获得性耐药的机制、敏感性与耐药的生物标志物、耐药的克服策略、肿瘤异质性与克隆演进。
- Pharmacogenomics: effects of germline and somatic variation on drug response, genetic differences in drug-metabolising enzymes, individualised dosing, and clinical validation of pharmacogenomics.药物基因组学： 种系与体细胞变异对药效的影响、药物代谢酶的遗传差异、个体化给药、药物基因组学的临床验证。
- Precision medicine: molecular-typing-guided treatment selection, development and validation of companion diagnostics, basket and umbrella trials, and the practice of molecular tumour boards.精准医学： 分子分型指导的治疗选择、伴随诊断的开发与验证、篮子试验与伞式试验、分子肿瘤委员会的实践。
- Immunotherapy and cell therapy: immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and therapeutic antibodies and bispecific molecules.免疫治疗与细胞治疗： 免疫检查点抑制剂、细胞过继免疫治疗、癌症疫苗、治疗性抗体与双特异性分子。
- Molecular characterisation and new technology: large-scale genomic and transcriptomic profiling, liquid biopsy and minimal residual disease, imaging and artificial intelligence, and clinical trial methodology.分子表征与新技术： 大规模基因组与转录组表征、液体活检与微小残留病、影像与人工智能、临床试验方法学。
The journal is published by the association itself under a hybrid model with Creative Commons licensing. The publisher gives a journal impact factor of 10.9, with 11.6 over five years and a journal citation indicator of 2.34本刊为该会自行出版，采用知识共享许可的混合出版模式；出版方公布的期刊影响因子为 10.9（五年 11.6、期刊引文指标 2.34），引用分数官方未列，审稿时效与录用比例官方未公布。 no CiteScore is listed and neither review speed nor acceptance rate is published.[1]
History
- Founding (1995): the journal was founded in 1995 under its present name, with no predecessor title and no renaming. According to the association's own narrative history, the rationale was a recognised need for an outlet focused on the clinical application of molecular biological discoveries.创刊（1995年）： 1995 年创刊，创刊即使用现名，无前身刊名亦无改名。据该会自身的会史记载，创刊动因是协会认定需要一份专注于分子生物学发现之临床应用的刊物。[2]
- Frequency: the journal began monthly and later expanded to two issues a month while still forming one volume a year. It also publishes continuously online, with meeting abstracts and research articles scheduled separately.刊期沿革： 创刊时为月刊，其后扩版为每月两期，每年仍编为一卷；本刊同时以在线方式连续出版，会议摘要与研究文章分别编排。
- Journal development (2024): in 2024 the journal established an early career award recognising young investigators in clinical and translational oncology, and the association expanded its editorial and commentary sections in the same period.刊物建设（2024年）： 2024 年本刊设立早期职业奖，用于表彰临床与转化肿瘤学领域的青年研究者；该会同期扩充了本刊的社论与评论栏目。
- Metrics and indexing: the impact factor of 10.9 is on the 2025 Journal Citation Reports released by Clarivate in 2026. The journal is indexed in MEDLINE, the Science Citation Index, Scopus, Current Contents and Web of Science.指标与收录： 影响因子 10.9，为科睿唯安 2026 年发布的 2025 年期刊引证报告口径；本刊被 MEDLINE、科学引文索引、Scopus、现刊目次与 Web of Science 收录。[1]
Editors
The journal has a fairly complete official record of editorial succession, with all six editors drawn from major North American cancer centres. The present editor-in-chief comes from the MD Anderson Cancer Center and took up the post in February 2025.本刊的主编沿革有较完整的官方记录，六任主编均来自北美主要癌症中心；现任主编来自MD 安德森癌症中心，2025 年 2 月就任。[3]
- Present editor-in-chief: Timothy A. Yap of the MD Anderson Cancer Center works on DNA damage repair and the early clinical development of targeted therapies, and took up the post in February 2025.现任主编： （Timothy A. Yap）供职于MD 安德森癌症中心，研究方向为 DNA 损伤修复与靶向治疗的早期临床开发，2025 年 2 月就任。
- Past editors: the founding editor was John Mendelsohn, serving from 1995 to 2004. He was followed by William N. Hait from 2005 to 2007, Eric Rubin in an interim role in 2007, Kenneth C. Anderson from 2008 to 2016 and Keith T. Flaherty from 2017 to 2025.历任主编： 首任主编为（John Mendelsohn），1995 年至 2004 年在任；其后依次为（William N. Hait）2005 年至 2007 年、（Eric Rubin）2007 年过渡、（Kenneth C. Anderson）2008 年至 2016 年、（Keith T. Flaherty）2017 年至 2025 年。[4]
- Conflict over tenure: the year in which Keith T. Flaherty took up the post is in conflict, with the association's personal page giving 2016 and its annual report January 2017任期冲突： 关于（Keith T. Flaherty）的就任年份存在冲突，该会个人页记 2016 年起，该会年报记 2017 年 1 月就任，两说并存。 both accounts are recorded.[5]